CL2016001813A1 - Use of gsk-j4 in the prevention and / or treatment of transplant rejection. - Google Patents

Use of gsk-j4 in the prevention and / or treatment of transplant rejection.

Info

Publication number
CL2016001813A1
CL2016001813A1 CL2016001813A CL2016001813A CL2016001813A1 CL 2016001813 A1 CL2016001813 A1 CL 2016001813A1 CL 2016001813 A CL2016001813 A CL 2016001813A CL 2016001813 A CL2016001813 A CL 2016001813A CL 2016001813 A1 CL2016001813 A1 CL 2016001813A1
Authority
CL
Chile
Prior art keywords
gsk
treatment
prevention
transplant rejection
transplanted
Prior art date
Application number
CL2016001813A
Other languages
Spanish (es)
Inventor
Cuadra Cristian Doñas
Lopez Macarena Carrasco
Kelly Macarena Fritz
Pedevila Alejandra Loyola
Silber Mario Rosemblatt
Original Assignee
Fund Ciencia Para La Vida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Ciencia Para La Vida filed Critical Fund Ciencia Para La Vida
Priority to CL2016001813A priority Critical patent/CL2016001813A1/en
Publication of CL2016001813A1 publication Critical patent/CL2016001813A1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>Uso de GSK-J4 para la prevención y/o tratamiento de rechazo de órganos en trasplante de órganos, tejidos o células, enfermedades autoinmunes y enfermedades inflamatorias crónicas. Kits terapéuticos que comprenden composiciones farmacéuticas que contienen GSK-J4, útiles para el tratamiento sistémico o local con GSK-J4 de pacientes trasplantados o que se van a trasplantar, o para el tratamiento de dichos pacientes con células tolerogénicas (Treg y/o tolDCs) generadas in vitro o ex vivo, pretratadas con GSK-J4.  </p><p> Use of GSK-J4 for the prevention and / or treatment of organ rejection in organ, tissue or cell transplantation, autoimmune diseases and chronic inflammatory diseases. Therapeutic kits comprising pharmaceutical compositions containing GSK-J4, useful for systemic or local treatment with GSK-J4 of patients transplanted or to be transplanted, or for the treatment of said patients with tolerogenic cells (Treg and / or tolDCs) generated in vitro or ex vivo, pretreated with GSK-J4. </p>

CL2016001813A 2016-07-15 2016-07-15 Use of gsk-j4 in the prevention and / or treatment of transplant rejection. CL2016001813A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2016001813A CL2016001813A1 (en) 2016-07-15 2016-07-15 Use of gsk-j4 in the prevention and / or treatment of transplant rejection.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2016001813A CL2016001813A1 (en) 2016-07-15 2016-07-15 Use of gsk-j4 in the prevention and / or treatment of transplant rejection.

Publications (1)

Publication Number Publication Date
CL2016001813A1 true CL2016001813A1 (en) 2018-03-09

Family

ID=63046355

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001813A CL2016001813A1 (en) 2016-07-15 2016-07-15 Use of gsk-j4 in the prevention and / or treatment of transplant rejection.

Country Status (1)

Country Link
CL (1) CL2016001813A1 (en)

Similar Documents

Publication Publication Date Title
NI201100083A (en) COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS.
CL2012002882A1 (en) Compounds derived from 5,7-substituted -imidazol [1,2-c] pyrimidines, jak kinase inhibitors; Preparation process; pharmaceutical composition; and its use to treat an autoimmune or inflammatory disease, the rejection of transplantation of organs, tissues or cells in a mammal.
NI201500067A (en) PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
CO2020004906A2 (en) Compositions and methods for the elimination of cd117 + cells
UY37565A (en) IARN ALFA-1 ANTITRIPSIN AGENTS (AAT), COMPOSITIONS INCLUDING IARN AAT AGENTS AND METHODS OF USE
CO7350624A2 (en) Bruton tyrosine kinase inhibitors
CL2008001620A1 (en) Induction of the tolerogenic phenotype in mature dendritic cells
CL2018000413A1 (en) Composition and products comprising senescent cells for use in tissue regeneration
MX2020005849A (en) Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof.
EA201890516A1 (en) CLINICAL COMPOSITIONS
MX2021010536A (en) Use of microparticles and endothelial cells with decellularized organs and tissues.
CO2020016052A2 (en) Chimeric growth factor receptors
CO2021003290A2 (en) Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained therefrom and compositions comprising them.
CO2021006259A2 (en) Antibody and drug conjugates (caf) with fc silencing and their uses
CO2020006855A2 (en) Compositions and methods for cd2 + cell depletion
WO2017136731A8 (en) Rapaglutins, novel inhibitors of glut and use thereof
MX2019004402A (en) Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators.
ECSP20000655A (en) IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF ALFA-ENaC AND METHODS OF USE
EA201790883A1 (en) TOLEROGENIC DENDRITIC CELLS, METHODS OF THEIR RECEIVING AND THEIR APPLICATION
BR112014026606A2 (en) methods for induction of antigen-specific regulatory t-cells
TR201902755T4 (en) LYOPHILIZED TRIPEPTIDE FORMULATIONS WITH STORAGE STABILITY.
AR077309A1 (en) CELLS DERIVED FROM CARDIAC TISSUE
CL2016001813A1 (en) Use of gsk-j4 in the prevention and / or treatment of transplant rejection.
CR20170296A (en) Methods for develoment and use of minimally polarized funcrion cell micro-aggregate units in tisseu applications using lgr4, lgr5 and lgr6 expresing epithelial stem cells
ES2434853B1 (en) Molecular marker of therapeutic potency of human mesenchymal stem cells and their uses